Pharmaceutical - Johnson & Johnson, Diabetes

Filter

Current filters:

Johnson & JohnsonDiabetes

Popular Filters

UK’s NICE backs Janssen’s Invokana for type 2 diabetes

16-05-2014

Janssen, a subsidiary of US health care giant Johnson & Johnson, said today that it welcomes the publication…

DiabetesInvokanaJanssenJohnson & JohnsonPharmaceuticalPricingRegulationUK

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

US FDA calls for more data on Janssen’s fixed dose diabetes drug

US FDA calls for more data on Janssen’s fixed dose diabetes drug

16-12-2013

US health care giant Johnson & Johnson has received a complete response letter from the Food and Drug…

canagliflozinDiabetesJanssenJohnson & JohnsonmetforminNorth AmericaPharmaceuticalRegulation

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA

25-11-2013

It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide

24-06-2013

Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA

02-04-2013

There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

FDA panel backs J&J diabetes drug Invokana (canagliflozin)

11-01-2013

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

canagliflozinDiabetesInvokanaJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021

16-10-2012

The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesJanuviaJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceutical

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA

27-06-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag International…

Anti-viralscanagliflozinDiabetesEgriftaEuropeFerrer InternacionalJanssenJohnson & JohnsonPharmaceuticalRegulation

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy

18-05-2012

Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

Russia’s type 2 diabetes drug market will grow to $1.7 billion in 2015

13-10-2011

Russia’s type 2 diabetes drug market will grow more than seven percent annually from $1.2 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesEuropeJohnson & JohnsonMarkets & MarketingPharmaceutical

Back to top